JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib

Ann Hematol. 2015 Nov;94(11):1929-30. doi: 10.1007/s00277-015-2454-4. Epub 2015 Jul 23.

¹ Department of Hematology and Oncology, University of Frankfurt, Frankfurt, Germany.
² Medizinische Fakultaet, University of Leipzig, Leipzig, Germany.
³ Institute of Pathology, University Hospital of Halle, Halle, Germany.
⁴ Novartis Pharma AG, Basel, Switzerland.
⁵ Department of Hematology/Oncology, University Hospital of Leipzig, Leipzig, Germany.
⁶ Institute of Pathology, University Hospital of Leipzig, Leipzig, Germany.
⁷ Department of Hematology/Oncology, University Hospital of Leipzig, Leipzig, Germany. alah@medizin.uni-leipzig.de.

No abstract available

Publication types